idalopirdine
Jump to navigation
Jump to search
Contraindications
* idalopirdine failed to slow cognitive decline in patients with Alzheimer's disease in phase 3 trial[1]
* of no benefit added to a cholinesterase inhibitor[2][3]
Mechanism of action
More general terms
References
- ↑ 1.0 1.1 Fiore K NeuroBreak: Alzheimer's Drug Bombs; Elephant Tranquilizer ODs. MEDPAGE TODAY. Sept 27, 2016 http://www.medpagetoday.com/Neurology/GeneralNeurology/60482
- ↑ 2.0 2.1 Fiore K AAIC 2017 Meeting Coverage. 5HT6 Blocker a Dud in Alzheimer Trials - May shake confidence in similar drugs being developed. https://www.medpagetoday.com/MeetingCoverage/AAIC/66784
- ↑ 3.0 3.1 Atri A, Frolich L, Ballard C et al Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease. Three Randomized Clinical Trials. JAMA. 2018;319(2):130-142 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29318278 https://jamanetwork.com/journals/jama/article-abstract/2668349
Bennett DA Lack of Benefit With Idalopirdine for Alzheimer Disease. Another Therapeutic Failure in a Complex Disease Process. JAMA. 2018;319(2):123-125. Jan 9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29318261 https://jamanetwork.com/journals/jama/article-abstract/2668332